Suven Life secures two product patents in India and Japan; shares rise

Suven Life Sciences on Monday announced that it has secured two (2) product patents in India and Japan corresponding to the New Chemical Entities (NCEs) for the treatment of Neurodegenerative diseases. 

For India and Japan the patents are valid through 2026 and 2032 respectively. The patents are from the mechanism of action include the class of selective 5-HT6 compounds and H3 Inverse agonist compounds, the company said in a regulatory filing.

These compounds are useful for the treatment of disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Major Depressive disorder (MDD), Parkinson and Schizophrenia.

Talking about the new patents, Venkat Jasti, CEO of Suven, said, "Suven has three clinical stage compounds, a Phase 2 undergoing candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 undergoing candidate SUVN-D4010 for Alzheimer’s disease and Schizophrenia. In addition to that the Company has ten internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain".

With the addition of these two new patents, now the company has total of 19 grated patents from India and 19 patents from Japan. 

Following the announcement, at 1358 hours, the shares of the company were trading at Rs 189.10 per piece, up 0.40%, or Rs 0.75 on BSE.